Works matching IS 15391604 AND DT 2019 AND VI 18 AND IP 2

Results: 12

On weighted composite scores for early Alzheimer's trials.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 239, doi. 10.1002/pst.1920

By:

Jin, Kun;
Cameron, Briana;
Dunn, Billy

Publication type:

Article

Investigation of the properties of the "switching decision rule" described in the Japanese guideline for human bioequivalence studies.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 260, doi. 10.1002/pst.1922

By:

Ii, Yoichi

Publication type:

Article

Study design aspects and inter‐subject variability in longitudinal clinical phase II dose‐finding trials.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 248, doi. 10.1002/pst.1921

By:

Kennes, Lieven Nils;
Volkers, Gisela;
Kralidis, Georg

Publication type:

Article

Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 140, doi. 10.1002/pst.1935

By:

Hemmings, Robert;
Koch, Armin

Publication type:

Article

Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 126, doi. 10.1002/pst.1919

By:

Dane, Aaron;
Spencer, Amy;
Rosenkranz, Gerd;
Lipkovich, Ilya;
Parke, Tom

Publication type:

Article

Propensity‐score‐based priors for Bayesian augmented control design.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 223, doi. 10.1002/pst.1918

By:

Lin, Junjing;
Gamalo‐Siebers, Margaret;
Tiwari, Ram

Publication type:

Article

Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 145, doi. 10.1002/pst.1917

By:

Rufibach, Kaspar

Publication type:

Article

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 166, doi. 10.1002/pst.1915

By:

Unkel, Steffen;
Amiri, Marjan;
Benda, Norbert;
Beyersmann, Jan;
Knoerzer, Dietrich;
Kupas, Katrin;
Langer, Frank;
Leverkus, Friedhelm;
Loos, Anja;
Ose, Claudia;
Proctor, Tanja;
Schmoor, Claudia;
Schwenke, Carsten;
Skipka, Guido;
Unnebrink, Kristina;
Voss, Florian;
Friede, Tim

Publication type:

Article

Phase II trial design with growth modulation index as the primary endpoint.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 212, doi. 10.1002/pst.1916

By:

Wu, Jianrong;
Chen, Li;
Wei, Jing;
Weiss, Heidi;
Miller, Rachel W.;
Villano, John L.

Publication type:

Article

Bayesian sample size determination for phase IIA clinical trials using historical data and semi‐parametric prior's elicitation.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 198, doi. 10.1002/pst.1914

By:

Berchialla, Paola;
Zohar, Sarah;
Baldi, Ileana

Publication type:

Article

A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 184, doi. 10.1002/pst.1913

By:

Homma, Gosuke;
Daimon, Takashi

Publication type:

Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 123, doi. 10.1002/pst.1882
Publication type:: Article